CNR2 and myeloid sarcoma: CB2 activation attenuates chemokine signaling, limits T cell invasion on patrolling inflammatory cells, and decreases astrocyte and microglia release of inflammatory mediators, such as IL-1β, TNF-α, etc. In preclinical models of MS, CB2 agonists display a decrease in demyelination and neuronal loss, demonstrating that the ECS has therapeutic possibilities in neuroinflammation [162,163,164].